News

Low blood levels of the copper-carrying protein ceruloplasmin at diagnosis are associated with worse survival in adults with ANCA-associated vasculitis (AAV) who test positive for self-reactive antibodies against the myeloperoxidase (MPO) enzyme, a new study from France has shown. “This is the first study associating low [blood] ceruloplasmin level…

ADX-097, an experimental tissue-targeted therapy that Q32 Bio is developing for ANCA-associated vasculitis (AAV) and other diseases marked by overactivity of the immune complement system, was well tolerated in a Phase 1 clinical trial involving healthy volunteers. The study’s data also indicated that ADX-097 showed a favorable pharmacological…

The long-term use of Nucala (mepolizumab) reduces disease activity and the need for standard glucocorticoids, while improving survival, in people with eosinophilic granulomatosis with polyangiitis (EGPA), the rarest type of ANCA-associated vasculitis (AAV). These are the findings of a real-world study in Japan that compared outcomes between 37…

The Vasculitis Foundation has announced the launch of a new support group for young adults with vasculitis, a group of autoimmune conditions that includes ANCA-associated vasculitis (AAV). The group will promote connections among young adults, from 18 to 30 years of age, living with vasculitis, which is marked by…

People with ANCA-associated vasculitis (AAV) have a higher risk of cardiovascular diseases and related mortality than people without the disease, according to a systematic review and meta-analysis of published studies. For example, the risk of venous thromboembolism, a blood clot that develops in a vein, was three times higher…

A Phase 1 clinical trial evaluating the safety and preliminary efficacy of Adicet Bio’s CAR T-cell therapy ADI-001 in people with autoimmune diseases, including ANCA-associated vasculitis (AAV), has started recruiting certain participants — and it’s expected to enroll AAV patients by the end of the year — the…

Patterns of lung damage on CT scans may help predict disease outcomes in people with ANCA-associated vasculitis (AAV) and determine which patients should receive more intensive treatment, a study in Germany suggests. Particularly, ground glass opacities (GGO), which are white diffuse regions due to fluid, airway collapse, tissue scarring,…

A European Medicines Agency (EMA) committee has issued a positive opinion recommending the approval of Fasenra (benralizumab) as an add-on treatment for adults with hard-to-treat eosinophilic granulomatosis with polyangiitis (EGPA). If approved for the recommended indication, the AstraZeneca therapy would be a new option for patients in…

High blood levels of the syndecan-1 protein, known to promote the survival of antibody-producing B cells, may help identify ANCA-associated vasculitis (AAV) patients with high disease activity — and those at risk of a poor prognosis — a new study suggests. The researchers defined two cut-off values of syndecan-1…

The U.S. Food and Drug Administration (FDA) has approved Fasenra (benralizumab) for treating adults with eosinophilic granulomatosis with polyangiitis (EGPA), a rare form of ANCA-associated vasculitis (AAV). Developed by AstraZeneca, Fasenra was already approved in more than 80 countries, including the U.S., as an add-on treatment…